Amgen’s Aranesp Gets Broader Label
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA provides small boost for safety-challenged ESA.
You may also be interested in...
Amgen’s Anemia Drugs Weaken In First Quarter
“Trust us” on unchanged revenue guidance, CEO says.
Amgen’s Aranesp, Procrit CIA Indications Okay For Incurable Cancers - ODAC
Panel suggests new label saying the chemotherapy-induced anemia treatments are not indicated for patients with curable cancers, breast cancer or head and neck tumors.
Aranesp “Complete Response” Letter Seeks Additional Clinical Data On Monthly Dosing
Amgen hopes to respond to FDA request with already collected data.